TipRanks
Global Pharmatech Inc (GBLP)
OTHER OTC:GBLP
US Market
GBLP
Global Pharmatech
RESEARCH TOOLSreports

Global Pharmatech (GBLP) Ratios

6 Followers

Global Pharmatech Ratios

GBLP's free cash flow for Q1 2026 was $0.24. For the 2026 fiscal year, GBLP's free cash flow was decreased by $ and operating cash flow was $0.15. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
 0.66 0.44 0.32 0.31
Quick Ratio
 0.64 0.41 0.27 0.27
Cash Ratio
 0.10 0.03 0.03 0.05
Solvency Ratio
 0.04 -0.07 0.05 0.33
Operating Cash Flow Ratio
 -0.10 0.02 -0.33 0.63
Short-Term Operating Cash Flow Coverage
 -1.22 0.19 0.00 7.83
Net Current Asset Value
$ -368.04K$ -485.67K$ -411.53K$ -430.02K
Leverage Ratios
Debt-to-Assets Ratio
 0.09 0.11 0.00 0.12
Debt-to-Equity Ratio
 -10.01 -0.67 0.00 -0.25
Debt-to-Capital Ratio
 1.11 -2.01 0.00 -0.34
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 -117.69 -6.25 -2.02 -2.18
Debt Service Coverage Ratio
 0.52 -0.74 80.93 4.14
Interest Coverage Ratio
 32.23 -113.24 -379.56 -188.73
Debt to Market Cap
 <0.01 <0.01 0.00 <0.01
Interest Debt Per Share
 <0.01 <0.01 <0.01 <0.01
Net Debt to EBITDA
 -0.33 -0.85 -0.71 0.08
Profitability Margins
Gross Profit Margin
26.84%11.15%66.02%50.18%
EBIT Margin
8.45%-21.59%-208.11%-35.66%
EBITDA Margin
9.09%-19.27%44.84%354.35%
Operating Profit Margin
6.37%-21.81%-210.28%-37.21%
Pretax Profit Margin
8.25%-21.78%-208.66%-35.85%
Net Profit Margin
8.25%-21.78%-208.66%-35.85%
Continuous Operations Profit Margin
8.25%-21.78%-208.66%-35.85%
Net Income Per EBT
100.00%100.00%100.00%100.00%
EBT Per EBIT
129.56%99.87%99.23%96.35%
Return on Assets (ROA)
4.03%-9.01%-34.09%-4.91%
Return on Equity (ROE)
-82.77%56.28%69.03%10.69%
Return on Capital Employed (ROCE)
-366.33%56.36%69.56%11.10%
Return on Invested Capital (ROIC)
40.68%169.86%69.56%14.89%
Return on Tangible Assets
4.45%-9.01%-34.09%-6.43%
Earnings Yield
0.13%-0.11%-0.15%-0.04%
Efficiency Ratios
Receivables Turnover
 0.94 0.95 0.47 0.43
Payables Turnover
 0.68 0.64 0.00 0.12
Inventory Turnover
 20.53 9.90 0.74 1.25
Fixed Asset Turnover
 6.71 3.70 0.63 0.46
Asset Turnover
 0.49 0.41 0.16 0.14
Working Capital Turnover Ratio
 -1.29 -0.69 -0.16 -0.24
Cash Conversion Cycle
 -129.80 -145.47 1.27K -1.81K
Days of Sales Outstanding
 389.96 385.43 779.88 852.13
Days of Inventory Outstanding
 17.78 36.87 495.03 292.17
Days of Payables Outstanding
 537.54 567.76 0.00 2.96K
Operating Cycle
 407.74 422.30 1.27K 1.14K
Cash Flow Ratios
Operating Cash Flow Per Share
 >-0.01 <0.01 >-0.01 <0.01
Free Cash Flow Per Share
 >-0.01 0.00 0.00 <0.01
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 0.72 0.00 0.00 0.42
Dividend Paid and CapEx Coverage Ratio
 -3.61 1.00 -1.00 1.71
Capital Expenditure Coverage Ratio
 -3.61 1.00 -1.00 1.71
Operating Cash Flow Coverage Ratio
 -1.22 0.19 0.00 7.83
Operating Cash Flow to Sales Ratio
 -0.21 0.05 -3.00 6.68
Free Cash Flow Yield
-0.24%0.00%0.00%0.29%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 800.90 -762.50 -684.85 -2.69K
Price-to-Sales (P/S) Ratio
 63.82 198.76 1.43K 965.61
Price-to-Book (P/B) Ratio
 -3.67K -513.53 -472.74 -287.96
Price-to-Free Cash Flow (P/FCF) Ratio
 -415.99 0.00 0.00 347.33
Price-to-Operating Cash Flow Ratio
 -300.80 4.15K -476.00 144.52
Price-to-Earnings Growth (PEG) Ratio
 16.02 15.25 -2.28 35.91
Price-to-Fair Value
 -3.67K -513.53 -472.74 -287.96
Enterprise Value Multiple
 702.07 -1.03K 3.19K 272.59
Enterprise Value
 33.24M 61.85M 94.83M 56.59M
EV to EBITDA
 702.07 -1.03K 3.19K 272.59
EV to Sales
 63.79 198.93 1.43K 965.90
EV to Free Cash Flow
 -415.80 0.00 0.00 347.44
EV to Operating Cash Flow
 -300.66 4.15K -475.89 144.56
Tangible Book Value Per Share
 >-0.01 >-0.01 >-0.01 >-0.01
Shareholders’ Equity Per Share
 >-0.01 >-0.01 >-0.01 >-0.01
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 0.00
Revenue Per Share
 <0.01 <0.01 <0.01 <0.01
Net Income Per Share
 <0.01 >-0.01 >-0.01 >-0.01
Tax Burden
 1.00 1.00 1.00 1.00
Interest Burden
 0.98 1.01 1.00 1.01
Research & Development to Revenue
 0.00 0.00 0.00 0.00
SG&A to Revenue
 0.20 0.33 0.00 0.00
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 0.00
Income Quality
 -2.57 -0.22 1.44 -18.64
Currency in USD